Although PSA has continued to be an integral part of the post-treatment evaluation process, use of PSMA-based PET has ushered a new era by early detection of metastatic disease.33 This can potentially alter treatment decisions in several patients in the recurrent setting and might confound the prognostic link between BCR and OS. This evidence concerns the gene BCR and metastatic neoplasm.